title: The pharmacokinetics of once-daily oral 400 mg ofloxacin in patients with peritonitis complicating continuous ambulatory peritoneal dialysis.
abstract: Seven patients with end-stage renal disease requiring support by continuous ambulatory peritoneal dialysis received once-daily 400 mg oral ofloxacin for 7 days for the treatment of bacterial peritonitis. Serum and peritoneal dialysis fluid (PDF) were collected for assay throughout the course of the study and for 5 days thereafter. Ofloxacin, desmethyl ofloxacin and ofloxacin-N-oxide accumulated over the course of therapy and could still be detected in serum and PDF 5 days after the end of therapy. The mean elimination half-life of ofloxacin in serum was 32 +/- 7 h, desmethyl ofloxacin 45 +/- 26 h and for ofloxacin-N-oxide 44 +/- 15 h. The total mean recovery of ofloxacin and its metabolites from the PDF was 15.4%. This regimen results in serum and PDF concentrations likely to be effective for the treatment of infection for at least 10 days.
authors.affiliation: Bristol Centre for Antimicrobial Research and Evaluation, Southmead Health Services NHS Trust and University of Bristol, Department of Medical Microbiology, UK. lesassays@UKnequasaa.win-UK.net
authors.forename: C M
authors.initials: CM
authors.lastname: McMullin
authors.forename: N M
authors.initials: NM
authors.lastname: Brown
authors.forename: I M
authors.initials: IM
authors.lastname: Brown
authors.forename: C R
authors.initials: CR
authors.lastname: Tomson
authors.forename: L O
authors.initials: LO
authors.lastname: White
authors.forename: D S
authors.initials: DS
authors.lastname: Reeves
authors.forename: A P
authors.initials: AP
authors.lastname: MacGown
mesh_terms: D000368:Aged; D000890:Anti-Infective Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010538:Peritonitis / Q000378:metabolism* / Q000628:therapy
chemical_list: D000890:Anti-Infective Agents; D015242:Ofloxacin